ArticleBMC medical informatics and decision making2026
Dual-modality ultrasound radiomics of the medial gastrocnemius muscle for detecting diabetic peripheral neuropathy: a multicenter prospective study.
Article in BMC medical informatics and decision making, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic peripheral neuropathy (DPN) affects 20%-50% of patients with type 2 diabetes mellitus (T2DM), yet early screening is limited by restricted access to nerve conduction studies (NCS). We aimed to develop and validate a dual-modality ultrasound radiomics model combining B-mode ultrasound (BMUS) and shear wave elastography (SWE) of the medial gastrocnemius (MG) - an accessible surrogate reflecting neurogenic muscle atrophy - for noninvasive DPN detection.
methodsA total of 190 T2DM patients (380 limbs) enrolled between June 2025 and February 2026 were allocated to training (158 limbs), internal test (68 limbs), and external validation (154 limbs) cohorts. DPN was defined as abnormal nerve conduction in at least two peripheral nerves, per ADA criteria. MG BMUS and SWE images were acquired bilaterally by blinded ultrasonographers. Sequential ICC (≥ 0.75), Mann-Whitney U (P < 0.05), Spearman (|r| > 0.7), and elastic-net filtering of 1,888 features selected 14 final features (9 BMUS, 5 SWE). An XGBoost MG-RadScore was derived via ten-fold cross-validation and integrated with clinical predictors in a final combined model. Performance was assessed by AUC, calibration, Hosmer-Lemeshow test, DCA, and SHAP.
resultsDiabetes duration (OR 1.13, 95% CI: 1.07-1.19, P < 0.001) and right MG mean SWE modulus (RMG_SWEmean; OR 0.94, P = 0.022) were independent clinical predictors. The clinical model achieved AUCs of 0.741/0.780/0.783; the MG-RadScore model showed higher discrimination than it (0.833/0.788/0.804). The combined model achieved AUCs of 0.895 (95% CI: 0.839-0.940), 0.861 (95% CI: 0.745-0.949), and 0.854 (95% CI: 0.785-0.909). Calibration was satisfactory (Hosmer-Lemeshow P > 0.05); DCA confirmed favorable net benefit; SHAP identified diabetes duration as the top predictor, followed by MG-RadScore and RMG_SWEmean.
conclusionA dual-modality MG ultrasound radiomics model integrating BMUS and SWE features with diabetes duration and RMG_SWEmean accurately detects DPN, achieving AUCs above 0.85 across multicenter prospective cohorts. This muscle-targeted, SHAP-interpretable approach offers a noninvasive alternative to nerve sonography and may facilitate early DPN screening where NCS is unavailable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.